Immunovaccine Inc. (TSX-V: IMV) is focused on the commercialization of its patented vaccine delivery and enhancement technology, the DepoVax™ platform that boasts such benefits as enhanced efficacy with fewer doses. Positive pre-clinical safety and efficacy data generated by the DepoVax platform has attracted multiple partnerships. Immunovaccine has also signed four licensing deals with Pfizer Animal Health. Pfizer is using Immunovaccine's platform to develop new vaccines for livestock.
The Company’s focus on developing human health vaccines has led to the in-licensing of Survivac from Merck KGaA. Survivac is a novel cancer vaccine which targets multiple survivin-expressing solid tumors.
Immunovaccine has exclusive, worldwide rights to develop and commercialize the survivin-based vaccine and plans to formulate it in the DepoVax delivery platform. Taking the DPX-Survivac into an accelerated clinical program is a priority for the Company because of its broad market potential and its potential utility in several cancer indications. The National Cancer Institute (NCI) has ranked Survivin among the world’s top 25 most promising antigens.
Immunovaccine’s aggressive growth strategy is led by an experienced management and board, consisting of a former senior executive of Sanofi and a member of the Canadian Medical Hall of Fame. The Company has recently completed a phase I clinical trial for DPX-0907, a therapeutic vaccine based on the DepoVax technology.
Through its own biotech research and collaborations with partners, Immunovaccine has been honoured as one of Canada’s Top 10 Life Sciences Companies. Today, the company is advancing DepoVax-based vaccines in a variety of indications that range from cancer to autoimmune disease through its own pipeline and a number of strategic collaborations and alliances around the world.
To download our corporate fact sheet, click here.
